Pharma & Biotech
Novo Nordisk Faces a Demand Flood as Production Race Nears Critical Juncture
A pair of catalysts is converging on Novo Nordisk just as the Danish drugmaker scrambles to expand its manufacturing footprint....
Bayer’s Two-Front Offensive: Legal Closure Paves the Way for a Pipeline-Fueled Rebound
The Supreme Court’s 7–2 ruling excising thousands of Roundup claims from Bayer’s docket was the kind of event that sends...
Novo Nordisk’s Share Recovery Picks Up as Legal, Pipeline, and Pill Catalysts Converge
Novo Nordisk’s stock has clawed back more than a third of its losses since the March 2026 trough, closing at...
Bayer Juggles a $2.45 Billion Biotech Bet and a Washington Trade Probe
Bayer’s stock crept back above a closely watched technical threshold on Friday, but the real drama for the German healthcare...
Ocugen’s CFO Bets on Her Own Stock as a Packed Conference Schedule Previews a Pivotal Summer
The clinical calendar is tightening for Ocugen, and the stock is starting to stir in anticipation. Shares closed the week...
Outlook Therapeutics Rallies as July Puts Two Crossroads in Sharp Focus
The stock has more than doubled since late May, but the coming weeks will determine whether that momentum is sustainable...
Kuros Biosciences: Revenue Surges 72% But Shares Sink to 52-Week Low
Investors are being presented with two sharply conflicting narratives on Kuros Biosciences. The Swiss biotech firm reported a blistering 72%...
Medtronic’s Asian Push and Portfolio Reshuffle Fail to Lift Stock from Its Lows
Medtronic is shedding complexity. After spinning off its diabetes division, the medical-device giant now operates three core pillars — cardiovascular,...
Outlook Therapeutics’ July 16 Shareholder Vote to Decide Nasdaq Fate as FDA Decision Looms on July 29
Outlook Therapeutics enters a high-stakes July with two pivotal events that will shape its future. On the 16th, shareholders must...
Bayer’s All-or-Nothing Summer: A Supreme Court Ruling and a $7.25bn Settlement Duel
Two legal milestones are converging on Bayer within weeks, and the market is holding its breath. By the end of...
Popular News
-
SunHydrogen Set for European Debut with Groundbreaking Technology
-
Walgreens Implements Deep Restructuring Following Private Buyout
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
